Flex Pharma (FLKS) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Flex Pharma Reports Second Quarter 2016 Financial Results
August 3, 2016 7:00 AM EDT-- Single Agent Human Efficacy Study in NLC Fully Enrolled Ahead of Plan with Topline Results Expected by Year End --
-- Phase 2 MS Study of FLX-787 Initiated in June; Phase 2 ALS Study to Start in the Coming Months --
-- First Consumer Product Scientifically Proven to Treat and Prevent Muscle Cramps Launched in June --
Conference Call Scheduled Today at 8:45 a.m. ET
BOSTON--(BUSINESS WIRE)--... More
